Bilastine Safety in Lactation
There is insufficient human data to definitively recommend bilastine as safe during breastfeeding, and alternative antihistamines with established safety profiles should be used instead.
Evidence Gap and Current Status
The available evidence reveals a critical knowledge gap regarding bilastine use during lactation:
- No human lactation studies exist for bilastine specifically examining breast milk transfer, infant exposure levels, or adverse effects in breastfed infants 1
- Animal studies show bilastine was well-tolerated in pregnant/lactating rats at doses up to 1,000 mg/kg/day, but animal data cannot be directly extrapolated to human lactation safety 2
- A systematic review of antihistamines in breastfeeding identified studies for cetirizine, loratadine, and other agents, but bilastine was notably absent from the evidence base 1
Recommended Alternatives with Proven Safety
Use these antihistamines instead, as they have established safety data during breastfeeding:
First-Generation Antihistamines
- All first-generation antihistamines are considered safe during breastfeeding, with minimal amounts excreted in breast milk 3
- These agents would not cause adverse effects on breastfed infants 3
Second-Generation Antihistamines with Data
- Cetirizine and loratadine have documented relative infant doses below 5% (ranging from 0.3% to 4.5%), which is considered safe 1
- These agents have human lactation studies demonstrating low breast milk transfer 1
- All studied antihistamines are considered safe during breastfeeding with minimal breast milk excretion 3
Clinical Decision-Making Algorithm
When a breastfeeding patient requires antihistamine therapy:
First choice: Use cetirizine or loratadine, which have established human safety data during lactation 3, 1
If sedation is acceptable: Consider first-generation antihistamines, which have extensive safety experience 3
Avoid bilastine until human lactation data become available, despite its favorable safety profile in non-lactating populations 4
Important Caveats
- While bilastine demonstrates excellent safety in general populations (no sedation, no cardiotoxicity, favorable adverse effect profile similar to placebo) 4, this does not translate to lactation safety without specific human data
- The general principle that newer medications lack lactation data applies here—absence of evidence is not evidence of safety 1, 5
- Most antihistamine product labels recommend avoiding use during breastfeeding due to lack of evidence rather than documented harm 1
- The extensive knowledge gap on antihistamines and lactation necessitates using only those agents with established human data 1
The prudent approach prioritizes maternal treatment effectiveness while selecting from antihistamines with documented safety profiles in breastfeeding, rather than using bilastine where no human lactation data exist.